当前位置：
X-MOL 学术
›
JACC Heart Fail.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF
JACC: Heart Failure ( IF 10.3 ) Pub Date : 2024-06-12 , DOI: 10.1016/j.jchf.2024.04.018 William S Weintraub 1 , Paul Kolm 2 , Sarahfaye Dolman 2 , Maria Alva 3 , Deepak L Bhatt 4 , Zugui Zhang 5
JACC: Heart Failure ( IF 10.3 ) Pub Date : 2024-06-12 , DOI: 10.1016/j.jchf.2024.04.018 William S Weintraub 1 , Paul Kolm 2 , Sarahfaye Dolman 2 , Maria Alva 3 , Deepak L Bhatt 4 , Zugui Zhang 5
Affiliation
The efficacy of sotagliflozin in patients with diabetes and recent worsening of heart failure was shown in the SOLOIST-WHF trial. However, the cost-effectiveness of sotagliflozin in these patients has not been previously investigated.
中文翻译：
Sotagliflozin 在 SOLOIST-WHF 中的成本效益
SOLOIST-WHF 试验显示了 sotagliflozin 对糖尿病和最近心力衰竭恶化的患者的疗效。然而，之前尚未研究过索格列净在这些患者中的成本效益。
更新日期：2024-06-12
中文翻译：
Sotagliflozin 在 SOLOIST-WHF 中的成本效益
SOLOIST-WHF 试验显示了 sotagliflozin 对糖尿病和最近心力衰竭恶化的患者的疗效。然而，之前尚未研究过索格列净在这些患者中的成本效益。
京公网安备 11010802027423号